Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGWP.L Regulatory News (GWP)

  • There is currently no data for GWP

Director/PDMR Shareholding

30 Mar 2012 13:57

RNS Number : 4932A
GW Pharmaceuticals PLC
30 March 2012
 



 

GW Pharmaceuticals PLC Director/PDMR Shareholding

GW Pharmaceuticals PLC

30 March 2012

GW Pharmaceuticals PLC

GW Pharmaceuticals PLC ("GW Pharmaceuticals" or the "Company")

NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS

Porton Down, UK, 30th March 2012: GW Pharmaceuticals (AIM: GWP) hereby provides notification that the Company was notified on 29th March that Dr Geoffrey Guy, a Director and Executive Chairman of the Company, had completed the following series of transactions in the ordinary 0.1 pence shares of GW Pharmaceuticals plc.

On 26th March 2012, Dr Guy transferred 9,780 shares to his personal pension scheme. This transaction, representing less than 0.1% of the Company's current issued share capital, was completed when the middle market price was 90 pence per share.

On 27th March 2012, Dr Guy gifted 165,000 shares to a family member. This transaction, representing 0.12% of the Company's current issued share capital, was completed when the middle market price was 88 pence per share.

On 28th March 2012, Dr Guy gifted 200,000 shares to charity. This transaction, representing 0.15% of the Company's current issued share capital, was completed when the middle market price was 86.25 pence per share.

Following these transactions Dr Guy retains a beneficial interest in 17,187,654 GW Pharmaceuticals plc ordinary shares of 0.1 pence each, representing 12.9% of the Company's current issued share capital.

The total number of shares outstanding in the Company is 133,147,354 ordinary shares of 0.1 pence each.

Enquiries:

GW Pharmaceuticals PLC Tel: +44 (0)1980 557 000

Adam George, Company Secretary

Peel Hunt LLP (Nominated Adviser) Tel: +44 (0)207 418 8900

James Steel/Vijay Barathan

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSLLFEFVEIIVIF
Date   Source Headline
18th Feb 201410:20 amRNSBlocklisting Interim Review
12th Feb 20141:47 pmRNSAdditional Listing
10th Feb 20145:00 pmRNSPresenting at Leerink Global Healthcare Conference
5th Feb 20147:00 amRNSQ1 2014 Financial Results and Operational Progress
31st Jan 20143:17 pmRNSHolding(s) in Company
29th Jan 20147:00 amRNSNotice of Results
17th Jan 20145:11 pmRNSHolding(s) in Company
16th Jan 201411:13 amRNSAdditional Listing
15th Jan 20144:34 pmRNSHolding(s) in Company
15th Jan 20144:33 pmRNSHolding(s) in Company
14th Jan 20144:23 pmRNSClosing of U.S. Follow-on Offering of Nasdaq ADSs
14th Jan 20147:00 amRNSAgreement with Ipsen for Sativex in Latin America
13th Jan 20145:00 pmRNSHolding(s) in Company
13th Jan 20145:00 pmRNSHolding(s) in Company
9th Jan 20147:00 amRNSRaises $87.9m on NASDAQ in U.S. Follow-On Offering
6th Jan 201412:18 pmRNSResults of General Meeting
6th Jan 201412:13 pmRNSFiles Amendment to Registration Statement
20th Dec 20132:05 pmRNSNotice of General Meeting and Follow-On Offering
11th Dec 20137:00 amRNSU.S. Patent Allowance for Cannabinoids in Glioma
6th Dec 20135:52 pmRNSPublication of UK Annual Report and Accounts
2nd Dec 20137:00 amRNSPresenting at Piper Jaffray Health Care Conference
29th Nov 20132:00 pmRNSBlocklisting Application
27th Nov 20137:00 amRNSSativex Regulatory Approval in Switzerland
26th Nov 20135:51 pmRNSDirector/PDMR Shareholding
26th Nov 20137:00 amRNSFiling of U.S. Annual Report on Form 20-F
19th Nov 20137:00 amRNSFinal Results
18th Nov 20136:00 pmRNSGW Presenting at Jefferies Healthcare Conference
15th Nov 20137:00 amRNSUpdate on Epidiolex in Childhood Epilepsy
12th Nov 20137:01 amRNSNotice of Results
11th Nov 20137:00 amRNSPhase 1b/2a trial for Glioblastoma Multiforme
21st Oct 20137:00 amRNSSuccessful Closing of Mutual Recognition Procedure
2nd Oct 20138:00 amRNSNew Sativex Data at ECTRIMS
24th Sep 20132:01 pmRNSGrant of Options
23rd Sep 201311:41 amRNSAgreement on Sativex Pricing in Germany
20th Sep 20137:00 amRNSPresenting at Aegis Capital Healthcare Conference
18th Sep 20137:00 amRNSGW Commences Trial of GWP42006 for Epilepsy
19th Aug 20137:00 amRNSBlocklisting Interim Review
14th Aug 20137:00 amRNSInvestigational New Drug Application for Sativex
8th Aug 20137:00 amRNSPresenting at the Canaccord Genuity Conference
5th Aug 20137:00 amRNS2013 Third Quarter Financial Results
5th Aug 20137:00 amRNSSativex MS Spasticity Cognition Study Results
22nd Jul 20137:00 amRNSFiles new application to expand Sativex to France
15th Jul 20137:00 amRNSNotice of Results
8th Jul 20137:00 amRNSProduct Launch
4th Jul 20138:31 amRNSHolding(s) in Company
10th Jun 201312:53 pmRNSDirector/PDMR Shareholding
3rd Jun 20137:00 amRNSSecond Quarter Financial Results
30th May 20135:30 pmRNSExercise of Over-Allotment Option
14th May 20131:00 pmRNSNotice of Results
10th May 20134:28 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.